BOSTON--(BUSINESS WIRE)--Convergent Dental, Inc., a privately held dental device company, today announced that David Garabedian has joined the team as Vice President of Marketing. In this role, Mr. Garabedian will own all aspects of marketing for Convergent Dental’s flagship product Solea®, the first FDA cleared CO2 9.3 micron dental laser for hard, soft and osseous tissue procedures. In addition he will drive the company’s many upcoming innovations from concept to commercialization.
“It is rare to find an opportunity to lead the marketing efforts for a rapidly growing medical device company that combines such compelling technology with the ability to solve such a clear and relatable clinical problem,” said Garabedian. “I joined Convergent Dental because they are positioned to dramatically influence a new way to manage oral health and I am delighted to be entrusted with helping the company accelerate the next phase of exceptional growth.”
Garabedian brings over 15 years of medical device marketing experience to Convergent Dental and has a deep-rooted passion for building high performing teams, developing global brands and introducing breakthrough technologies with companies like Philips, C.R. Bard, Orthofix Orthopedics and Boston Scientific. He has a rich understanding of product positioning, branding and new product go-to-market planning, as well as a proven track record of delivering stable revenue growth for endoscopy, orthopedics, atrial fibrillation and emergency care products.
“The success of Convergent Dental can be attributed to our employees’ passion for excellence which Dave brings to us in spades,” said Michael Cataldo, CEO of Convergent Dental. “Our team is thrilled to have David on board, as his expertise in product marketing will accelerate the growth of Solea and all of our future innovations.”
About Convergent Dental, Inc.
Convergent Dental, Inc., is a privately owned dental equipment and technology company. We are the developer of Solea®, the first computer-aided, CO2 laser system to be cleared by the FDA for hard, soft and osseous tissue indications. With Solea’s unique wavelength and computer controls, dentists can reliably perform procedures anesthesia-free, blood-free, suture-free and pain-free. For dentists, reliably anesthesia-free and blood free procedures are powerful practice growth drivers, which enables multi-quadrant dentistry, saves time overall, allows dentists to perform more procedures themselves rather than refer patients out, and provides a more positive patient experience. For more information visit www.convergentdental.com. Follow the company on Twitter, Facebook, LinkedIn and Google+.
